BCG-SSI® vaccine-associated lymphadenitis : Incidence and management

Simple item page
dc.contributor.authorEngelis, Arnis
dc.contributor.authorKakar, Mohit
dc.contributor.authorMeikšāns, Roberts
dc.contributor.authorPetersons, Aigars
dc.contributor.institutionDepartment of Paediatric Surgery
dc.date.accessioned2021-06-22T10:05:01Z
dc.date.available2021-06-22T10:05:01Z
dc.date.issued2016
dc.descriptionPublisher Copyright: © 2016 The Lithuanian University of Health Sciences
dc.description.abstractBackground and objective There is a high incidence of childhood tuberculosis in Latvia, including children aged less than 1 year, while BCG-associated lymphadenitis is one of the most frequent adverse events requiring surgical treatment. The aim of this study was to analyze the incidence of purulent BCG adenitis through-out the population of Latvia after the introduction of BCG-SSI® vaccine and to evaluate the treatment results. Material and methods The study included 194 patients. All patients had received the BCG-SSI® vaccine during the first week of life routinely or at a later time according to the indications. The indications for surgical treatment were lymph node destruction also affecting the skin. All patients in this study received surgical treatment – the affected lymph node extirpation. Results The mean age of the patients was 5.12 ± 0.96 months. A total of 172 patients had purulent axillar lymphadenitis, 14 had purulent supraclavicular lymphadenitis, 8 patients had lymphadenitis at both localizations. During the whole study period the incidence of BCG adenitis varied from 0.02% to 0.36%, while the mean rate was 0.11% ± 0.08% from 184,068 vaccinated children during the study period. We observed an increasing trend in the incidence of BCG lymphadenitis during the study period. The primary and complete healing rate at the end of period was 99.5% (n = 193) following an affected lymph node extirpation. The mean hospitalization time after the operation was 3.71 ± 0.18 days. Conclusions The incidence of BCG-SSI® vaccine associated purulent lymphadenitis varied widely with an increasing trend, followed by the return to the product characteristic limits. Indications for the surgical treatment should not be changed. Extirpation of the purulent BCG adenitis is a safe treatment method and leads to the primary wound healing in the majority of cases.en
dc.description.statusPeer reviewed
dc.format.extent5
dc.format.extent463699
dc.identifier.citationEngelis, A, Kakar, M, Meikšāns, R & Petersons, A 2016, 'BCG-SSI ® vaccine-associated lymphadenitis : Incidence and management', Medicina (Lithuania), vol. 52, no. 3, pp. 187-191. https://doi.org/10.1016/j.medici.2016.05.001, https://doi.org/10.1016/j.medici.2016.05.001
dc.identifier.doi10.1016/j.medici.2016.05.001
dc.identifier.issn1010-660X
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/5414
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=84977488585&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofMedicina (Lithuania)
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBCG-SSI vaccine
dc.subjectComplications
dc.subjectLymphadenitis
dc.subjectPurulent BCG adenitis
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGeneral Medicine
dc.subjectSDG 3 - Good Health and Well-being
dc.titleBCG-SSI® vaccine-associated lymphadenitis : Incidence and managementen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
BCG_SSI_vaccine_associated_lymphadenitis.pdf
Size:
452.83 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure